LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.11 -0.89

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.1

Max

1.12

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-31M 72M
Vorheriger Eröffnungskurs	2
Vorheriger Schlusskurs	1.11

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Feb. 2026, 23:21 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. Feb. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. Feb. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. Feb. 2026, 23:06 UTC

Ergebnisse

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Shareholders to Receive A$5.20/Share in Cash

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. Feb. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. Feb. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. Feb. 2026, 20:48 UTC

Ergebnisse

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. Feb. 2026, 20:47 UTC

Ergebnisse

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. Feb. 2026, 20:46 UTC

Ergebnisse

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. Feb. 2026, 20:45 UTC

Ergebnisse

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. Feb. 2026, 20:43 UTC

Ergebnisse

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope Net Debt A$2.2 Million at Dec. 31

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. Feb. 2026, 20:41 UTC

Ergebnisse

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. Feb. 2026, 20:39 UTC

Ergebnisse

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Rating-Konsens

By TipRanks

Sell

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.